Market share clarification...Several people on the Yahoo thread have wondered out loud about the wholesale amount for the eye drugs, versus their retail price, in the mistaken belief that PARS' 20% cut would come from a *smaller* number than what we have seen conjectured in Sturza's medical newsletter, the Giza newsletter, etc.
The U.S. Alrex market is, for example, projected at $250 million.
If this were a wholesale number and the BOL/PARS team won 100% of it, we would get $250 million in revenue to divide up. If it were a retail number, however, we would first take a percentage off the top -- say 50%, lower the $250 to $125 million, and then get $125 million in revenue. Big difference.
Not to worry -- the second calculation is wrong. Use the first method. I have confirmed this information with the company by phone this morning.
Also, the company tells me that in the week just passed, there were no additional mortalities in the first two cohorts of HU-211 Phase II followup. That 6-month follow up period is now closed and we should be told at the annual meeting on Sept. 16 that the total mortality rate remained at 12.5% for the first two groups. Of course we may also be told the mortality rate for the placebo versus the HU-211 drug. At the outside we will receive this information in a press release in early October.
--Ariella |
